$EFOI 5.08M float, 1M shares are held by institutions. Net float is 4.08M. I checked its FTDs, over 5.1M. Isn’t this bullish? Current shortable shares are only 900 with a fee of 148% per Fintel. These 5.1M FTDs will be settled in mid Jan (T+35).
@Jonnyylove I don’t get why Bharat Bio’s WTO approval is a good news for OCGN. They are not related at all. OCGN is a contractor for Bharat to get US and Canada approval and sales thereafter. Since it failed to get FDA approval ( phase 3 should be conducted in the US to get FDA approval),
@TRUExDEMON The company can not dilute shares whenever they want. They should have a solid reason and the financial effect should be reported from dilution. They already accumulated $20M cash from 13.3M shares offering in early Oct. Yesterday they did debt to equity swap.
@MrZackMorris $BHAT. Strong fundamental and over $11M cash on hold. It announced very strong quaterly result with $0.003 eps and over 200% revenue increase yoy. Current price is $0.59. 3000% runner up potentially.
@MrZackMorris Good morning, Zack! $Fami is a great potential with strong financials (postive $0.05 eps in fiscal year 2020) and $87M cash on hand. Take a look. It could be more than 10X potential. #fintwit#High5StockGro https://t.co/4vo1lvtpVg
@MrZackMorris Zack, people are resenting you for $Dats dropping down because you mentioned other ticker for swing play. Please tell them you still hold $Dats.
@MrZackMorris Now it has $26M cash on hand with no debt. Strong buyout candidate. Next week will be an epic. Zack, your target price of $30-50 will be still good to go!
@MrZackMorris Zack! NTRB completed public offering and raised $6.6M cash in early Oct. Its sales are growing 150% yoy and started manufacturing Covid 19 antibody patch with its patented technology. Total outstanding shares after offering is less than 8M and current float is only 3M.